These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8319398)

  • 1. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
    Neal CE; Baker MR; Hilgers RD; Fanning J; Burke RC; Snodgrass J; Cull RD
    Clin Nucl Med; 1993 Jun; 18(6):472-6. PubMed ID: 8319398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
    Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
    Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT.
    Low RN; Carter WD; Saleh F; Sigeti JS
    Radiology; 1995 May; 195(2):391-400. PubMed ID: 7724757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoscintigraphy of colorectal carcinoma utilizing 111In-labeled monoclonal antibody conjugate CYT-103.
    Neal CE; Swan TL; Baker MR; Ellis RL; Katterhagen JG
    Gastrointest Radiol; 1991; 16(3):251-5. PubMed ID: 1879645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of immunoscintigraphy using a cocktail of radiolabeled monoclonal antibodies in the detection of colorectal cancer.
    Volpe CM; Abdel-Nabi HH; Kulaylat MN; Doerr RJ
    Ann Surg Oncol; 1998 Sep; 5(6):489-94. PubMed ID: 9754756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
    Method MW; Serafini AN; Averette HE; Rodriguez M; Penalver MA; Sevin BU
    Cancer; 1996 Jun; 77(11):2286-93. PubMed ID: 8635097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
    Gallup DG
    Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342
    [No Abstract]   [Full Text] [Related]  

  • 8. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
    Doerr RJ; Herrera L; Abdel-Nabi H
    Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
    Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
    Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer.
    Petersen BM; Bass BL; Bates HR; Chandeysson PL; Harmon JW
    Am J Surg; 1993 Jan; 165(1):137-42; discussion 142-3. PubMed ID: 8418688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature.
    Pinkas L; Robins PD; Forstrom LA; Mahoney DW; Mullan BP
    Nucl Med Commun; 1999 Aug; 20(8):689-96. PubMed ID: 10451876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management?
    Dominguez JM; Wolff BG; Nelson H; Forstrom LA; Mullan BP
    Dis Colon Rectum; 1996 May; 39(5):514-9. PubMed ID: 8620800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoscintigraphy using 111InCyt103 prior to second look laparotomy in ovarian cancer. A pilot study.
    Hempling RE; Piver MS; Baker TR; Bakshi S; Gilani SS
    Am J Clin Oncol; 1994 Aug; 17(4):331-4. PubMed ID: 8048395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-111 CYT-103 immunoscintigraphy of isolated splenic metastasis from ovarian carcinoma.
    Nguyen BD; Regan F
    Clin Nucl Med; 1997 Apr; 22(4):256-7. PubMed ID: 9099487
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111-labeled B72.3 monoclonal antibody.
    Krag DN; Ford P; Smith L; Taylor M; Schneider PD; Bushberg JT; Goodnight JE
    Arch Surg; 1993 Jul; 128(7):819-23. PubMed ID: 8317965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma.
    Markowitz A; Saleemi K; Freeman LM
    Clin Nucl Med; 1993 Aug; 18(8):685-700. PubMed ID: 8403703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis.
    Neal CE; Johnson DL; Cornwell VL; Markwell S
    Clin Nucl Med; 1996 Aug; 21(8):638-42. PubMed ID: 8853918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in immunoscintigraphy of ovarian cancer.
    Kim EE; Kasi LP
    Gynecol Oncol; 1993 Mar; 48(3):283-4. PubMed ID: 8462895
    [No Abstract]   [Full Text] [Related]  

  • 19. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
    Abdel-Nabi HH; Doerr RJ
    Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunodetection of colorectal carcinoma.
    Artiko V; Obradovic V; Davidovic B; Petrovic N; Petrovic M; Krivokapic Z; Kecmanovic D; Pesko P; Djukic V; Milosavljevic T; Adanja G; Vlajkovic M
    Hepatogastroenterology; 2003; 50(52):1029-31. PubMed ID: 12845972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.